| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice | Autoimmunity Reviews | 2015 | 150 |
| 2 | Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry | Autoimmunity Reviews | 2012 | 146 |
| 3 | Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases | Autoimmunity Reviews | 2021 | 140 |
| 4 | Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study | Clinical Rheumatology | 2017 | 115 |
| 5 | Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study | Clinical Rheumatology | 2016 | 95 |
| 6 | Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study | Clinical Rheumatology | 2017 | 84 |
| 7 | Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project | Annals of the Rheumatic Diseases | 2017 | 77 |
| 8 | Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study | Internal Medicine Journal | 2020 | 75 |
| 9 | A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome | Clinical Rheumatology | 2017 | 64 |
| 10 | Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study | Clinical Rheumatology | 2018 | 64 |
| 11 | Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations | Journal of rheumatology Supplement, The | 2014 | 61 |
| 12 | Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases | International Journal of Molecular Sciences | 2019 | 60 |
| 13 | Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients | Clinical Rheumatology | 2019 | 56 |
| 14 | Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study | Clinical Rheumatology | 2017 | 52 |
| 15 | Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease | Frontiers in Immunology | 2017 | 50 |
| 16 | The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease | Ocular Immunology and Inflammation | 2020 | 46 |
| 17 | Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study | British Journal of Ophthalmology | 2018 | 44 |
| 18 | Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study | Modern Rheumatology | 2017 | 38 |
| 19 | The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review | Rheumatology International | 2019 | 38 |
| 20 | The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy | Clinical Rheumatology | 2015 | 37 |
| 21 | Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis | Therapeutics and Clinical Risk Management | 2018 | 37 |
| 22 | Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis | Ocular Immunology and Inflammation | 2019 | 37 |
| 23 | New therapeutic solutions for Behçet’s syndrome | Expert Opinion on Investigational Drugs | 2016 | 36 |
| 24 | Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease | Clinical Rheumatology | 2017 | 36 |
| 25 | Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies | Clinical Rheumatology | 2018 | 35 |
| 26 | Kidney involvement in systemic sclerosis: From pathogenesis to treatment | Journal of Scleroderma and Related Disorders | 2018 | 32 |
| 27 | The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment | Trends in Cardiovascular Medicine | 2021 | 31 |
| 28 | Increased Bcl-2/p53 ratio in human osteoarthritic cartilage: a possible role in regulation of chondrocyte metabolism | Annals of the Rheumatic Diseases | 2005 | 29 |
| 29 | Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis | Clinical Rheumatology | 2019 | 29 |
| 30 | Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art | Clinical Rheumatology | 2016 | 28 |
| 31 | Untangling the Web of Systemic Autoinflammatory Diseases | Mediators of Inflammation | 2014 | 25 |
| 32 | Position paper of Italian rheumatologists on the use of biosimilar drugs | Clinical and Experimental Rheumatology | 2015 | 22 |
| 33 | Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab | Clinical Rheumatology | 2018 | 21 |
| 34 | Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease | Annals of the Rheumatic Diseases | 2019 | 21 |
| 35 | Recovery of erosive rheumatoid arthritis after human immunodeficiency virus-1 infection and hemiplegia | Journal of Rheumatology | 1997 | 21 |
| 36 | Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome | Clinical and Experimental Rheumatology | 2016 | 21 |
| 37 | Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI) | RMD Open | 2020 | 20 |
| 38 | Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis | Mediators of Inflammation | 2020 | 20 |
| 39 | Update on the Medical Management of Gastrointestinal Behçet’s Disease | Mediators of Inflammation | 2017 | 16 |
| 40 | Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases | Patient Preference and Adherence | 2018 | 15 |
| 41 | Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy | Clinical and Experimental Rheumatology | 2018 | 15 |
| 42 | Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series | BMC Research Notes | 2014 | 14 |
| 43 | Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis | Modern Rheumatology | 2017 | 13 |
| 44 | Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs | Clinical and Experimental Rheumatology | 2016 | 11 |
| 45 | Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis | Clinical Rheumatology | 2016 | 10 |
| 46 | Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis | Rheumatology | 2021 | 10 |
| 47 | Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA | Clinical and Experimental Rheumatology | 2019 | 10 |
| 48 | Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey | Clinical and Experimental Rheumatology | 2019 | 10 |
| 49 | Isolated thrombocytopenia associated with low dose methotrexate therapy | Clinical Rheumatology | 1997 | 9 |
| 50 | Management of Small Vessel Vasculitides | Current Rheumatology Reports | 2016 | 9 |
